6 completed, 3 terminated. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 3 |
Follow bermekimab: new trials by email Literature Review of bermekimab trials Research Report on bermekimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa Bermekimab, Adalimumab, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Janssen Research & Development, LLC | 151 | 2021-10-12 | 2023-11-13 |
| A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Bermekimab, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 6 | 2021-09-02 | 2023-05-24 |
| A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Placebo, Bermekimab, Dupilumab - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 199 | 2021-05-03 | 2023-03-01 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa bermekimab, placebo - Hidradenitis Suppurativa, Acne Inversa | Phase 2 | Completed | Janssen Research & Development, LLC | 153 | 2019-09-16 | 2023-07-27 |
| The Benefit of Bermekimab in Patients With Systemic Sclerosis MABp1 (Bermekimab) OR Placebo, MABp1 (Bermekimab) - Scleroderma, Systemic | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 20 | 2019-07-19 | 2022-09-29 |
| A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Xilonix - Pyoderma Gangrenosum | Phase 2 | Completed | Janssen Research & Development, LLC | 10 | 2014-01-31 | 2025-07-08 |
| Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris RA-18C3 - Acne Vulgaris | Phase 2 | Completed | Janssen Research & Development, LLC | 11 | 2012-02-29 | 2025-03-30 |
| Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis RA-18C3 - Psoriasis | Phase 2 | Completed | Janssen Research & Development, LLC | 8 | 2011-09-30 | 2025-03-30 |
| Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis. CV-18C3, Standard of Care - Patients Undergoing Repeat Peripheral Artery Revascularization | Phase 2 | Completed | Janssen Research & Development, LLC | 43 | 2011-06-30 | 2025-03-30 |
Dermatitis, Atopic (2) · Hidradenitis Suppurativa (2) · Acne Vulgaris (1) · Psoriasis (1) · Pyoderma Gangrenosum (1) · Scleroderma, Systemic (1)
Janssen Research & Development, LLC (8) · Hellenic Institute for the Study of Sepsis (1)
United States (8) · Canada (2) · Germany (2) · Japan (2) · Poland (2) · Argentina (1) · Australia (1) · Greece (1) · Netherlands (1) · Spain (1)
Hosam El-Sayed, M.D., Ph.D. (1) · Johann Gudjonsson, M.D., PhD (1) · Michael D Stecher, MD (1)